Distinct Conformations of Mirabegron Determined by MicroED
Source abstract
Abstract
Abstract Mirabegron, commonly known as “Myrbetriq”, has been widely prescribed as a medicine for overactive bladder syndrome for over a decade. However, the structure of the drug and what conformational changes it may undergo upon binding its receptor remain unknown. In this study, the authors employed microcrystal electron diffraction (MicroED) to reveal its elusive three‐dimensional (3D) structure. They find that the drug adopts two distinct conformational states (conformers) within the asymmetric unit. Analysis of hydrogen bonding and packing demonstrated that the hydrophilic groups are embedded within the crystal lattice, resulting in a hydrophobic surface and low water solubility. Structural comparison revealed the presence of trans ‐ and cis ‐ forms in conformers 1 and 2 , respectively. Comparison of the structures of Mirabegron alone with that of the drug bound to its receptor, the beta 3 adrenergic receptor (β3AR) suggests that the drug undergoes major conformational change to fit in the receptor agonist binding site. This research highlights the efficacy of MicroED in determining the unknown and polymorphic structures of active pharmaceutical ingredients (APIs) directly from powders.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Urinary Tract Infections Management · Spectroscopy and Quantum Chemical Studies · Molecular spectroscopy and chirality
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biological Chemistry University of California 615 Charles E. Young Drive South Los Angeles CA 90095 USA
Department of Physiology University of California 615 Charles E. Young Drive South Los Angeles CA 90095 USA
Howard Hughes Medical Institute University of California Los Angeles CA 90095 USA
Funding
National Institutes of Health · Howard Hughes Medical Institute
References (33)
Show source-provided references
1. 10.1016/j.molcel.2021.06.02410.1016/j.molcel.2021.06.024 ↗
2. 10.1517/17460441.2014.89292310.1517/17460441.2014.892923 ↗
3. 10.1124/jpet.106.11584010.1124/jpet.106.115840 ↗
4. 10.1111/ijcp.1243310.1111/ijcp.12433 ↗
5. 10.1073/pnas.190165511610.1073/pnas.1901655116 ↗
6. 10.3390/pharmaceutics1003014910.3390/pharmaceutics10030149 ↗
7. 10.1097/01.NPR.0000425824.44694.e810.1097/01.NPR.0000425824.44694.e8 ↗
8. Kane S. · ClinCalc DrugStats Database · 2020 · 20
9. 10.1017/S088571561700112910.1017/S0885715617001129 ↗
10. Tamayo A. P. · Rev. Invest. Univ. Quindío. · 2019 · 31
11. 10.1007/978-1-4939-7000-1_1010.1007/978-1-4939-7000-1_10 ↗
12. 10.1021/ja00501a00910.1021/ja00501a009 ↗
13. 10.7554/eLife.0134510.7554/eLife.01345 ↗
14. 10.1038/nmeth.304310.1038/nmeth.3043 ↗
15. 10.1039/C7CC03180G10.1039/C7CC03180G ↗
16. 10.1002/anie.20181131810.1002/anie.201811318 ↗
17. 10.1002/anie.20190456410.1002/anie.201904564 ↗
18. 10.1021/jacs.1c0172910.1021/jacs.1c01729 ↗
19. 10.1002/anie.20230376110.1002/anie.202303761 ↗
20. 10.1039/D1RA03100G10.1039/D1RA03100G ↗
21. 10.1002/anie.20211498510.1002/anie.202114985 ↗
22. 10.1038/s42004-022-00804-210.1038/s42004-022-00804-2 ↗
23. 10.1039/D2CE01522F10.1039/D2CE01522F ↗
24. 10.1021/acs.cgd.3c0043210.1021/acs.cgd.3c00432 ↗
25. Burch J. E. · ChemRxiv · 2021
26. 10.1021/acscentsci.8b0076010.1021/acscentsci.8b00760 ↗
27. 10.1107/S205225251901058310.1107/S2052252519010583 ↗
28. 10.1107/S090744490904733710.1107/S0907444909047337 ↗
29. 10.1107/S090744490904737410.1107/S0907444909047374 ↗
30. 10.1107/S205327331402637010.1107/S2053273314026370 ↗
31. 10.1107/S205322961402421810.1107/S2053229614024218 ↗
32. 10.1007/b13561810.1007/b135618 ↗
33. 10.1016/S0022-2860(98)00806-010.1016/S0022-2860(98)00806-0 ↗